immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (TUMAPs) that are associated with particular cancers.
http://www.immatics.mobi/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
0.8 seconds
16x16
32x32
Immatics Biotechnologies GmbH
Silvio Rometsch
Paul-Ehr●●●●●●●●rasse 15
Tue●●●gen , 72076
DE
View this contact
Immatics Biotechnologies GmbH
Silvio Rometsch
Paul-Ehr●●●●●●●●rasse 15
Tue●●●gen , 72076
DE
View this contact
Domainfactory GmbH
Hostmaster Domainfactory
Oskar-M●●●●●●●Str. 33
Ism●●●ing , 85737
DE
View this contact
BUY YOUR DOMAIN
Tucows Domains Inc. (69)
WHOIS : whois.dotmobiregistry.net
REFERRED :
PAGES IN
THIS WEBSITE
2
SSL
EXTERNAL LINKS
0
SITE IP
185.21.102.133
LOAD TIME
0.833 sec
SCORE
6.2
Home - Immatics | immatics.mobi Reviews
https://immatics.mobi
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (TUMAPs) that are associated with particular cancers.
immatics.mobi
immatics biotechnologies - active against cancer
http://www.immatics.mobi/index.php?PHPSESSID=007fd3093eeee3bf4e1dce23f5d45ade
Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Model.php. Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Model.php. Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Controler.php. MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology. Collaboration Aims ...
immatics biotechnologies - active against cancer
http://www.immatics.mobi/index.php?page=91&modid2=2013&PHPSESSID=007fd3093eeee3bf4e1dce23f5d45ade
Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Model.php. Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Model.php. Assigning the return value of new by reference is deprecated in /kunden/395346 72076/webseiten/IMMATICS LIVE/LIMECMS3/oos3/Controler.php. EU-funded HepaVAC project to develop a vaccine for liver cancer has kicked off. EU-funded IMMOMEC conso...
TOTAL PAGES IN THIS WEBSITE
2
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
Home - Immatics
Bringing the Power of T cells to Cancer Patients. Proprietary and Partnered Immune-oncology Programs. World Class Team and Science. Go to Bispecific TCR Molecules. Immatics has developed three innovative approaches to producing Adoptive Cell Therapies (ACT): ACTolog. These therapies are directed against targets which will transform the current landscape of tumor therapy. Bispecific T-Cell Receptor Molecules. About Bispecific T-Cell receptor molecules. MorphoSys and Immatics Biotechnologies Enter Strategi...
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
Home - Immatics
Bringing the Power of T cells to Cancer Patients. Proprietary and Partnered Immune-oncology Programs. World Class Team and Science. Go to Bispecific TCR Molecules. Immatics has developed three innovative approaches to producing Adoptive Cell Therapies (ACT): ACTolog. These therapies are directed against targets which will transform the current landscape of tumor therapy. Bispecific T-Cell Receptor Molecules. About Bispecific T-Cell receptor molecules. MorphoSys and Immatics Biotechnologies Enter Strategi...
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatics biotechnologies - active against cancer
Is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer. Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies. Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer. Immaticsâ contribution to validation of tumour mutations by mass spectrometry published in Nature.
immatinymonster.deviantart.com
immatinymonster (sarahhhh) - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 6 Years. This deviant's full pageview. Last Visit: 210 weeks ago. This is the place where you can personalize your profile! Life is...
人の役に立つアルバイト | 人に感謝されながら働くって気持ちいい！
Proudly powered by WordPress. Theme: Sixhours by Caroline Moore.
Vente de Mobil home dans le 63. - Immat loisirs
Contactez-nous au : 04.73.88.85.86. Bienvenue sur le site d' Immatloisirs , vente de chalets en bois, madriers, rondins ou ossature à Murol dans le Puy-de-Dôme (63). Immatloisirs est une entreprise qui vend des chalets en bois, madriers, rondins ou ossature, des résidences mobiles de loisirs et des accessoires et de l'équipement. Nous sommes situés à Murol dans le Puy-de-Dôme. Nous vous proposons également un ensemble de produits d'occasion que vous pouvez trouver dans la rubrique. Retour en haut de page.
SOCIAL ENGAGEMENT